Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01686620 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

A Phase 2 study, sponsored by Biodel.

Completed
Registry status
Phase 2
Development phase
132
Enrollment target

NCT01686620: Completed Phase 2 study, sponsored by Biodel.

NCT01686620 is a Phase 2 study that has completed, run by Biodel. The registered enrollment target is 132 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01686620, a Phase 2 study, has completed, sponsored by Biodel.

COMPLETED
Registry status
Phase 2
Development phase
132 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.

Interventions

  • DRUG BIOD-123
  • DRUG Lispro (Humalog)

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2012-08
Est. Completion 2013-06
Phase Phase 2
Biodel

6 total trials

What the finished NCT01686620 record still lists

NCT01686620 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which BIOD-123 is the first listed.

NCT01686620 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01686620 about?

NCT01686620 is a clinical study titled "A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)". The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.

What is the current status of trial NCT01686620?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2012-08. Estimated completion is 2013-06.

What interventions are being tested in trial NCT01686620?

The interventions under investigation include: BIOD-123 (DRUG), Lispro (Humalog) (DRUG).

Who is sponsoring clinical trial NCT01686620?

This trial is sponsored by Biodel, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01686620's enrollment target sits among peer trials

132 539th of 2000 higher than 1,460 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01766297 · 132 participants · Phase 2

    Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • NCT04002947 · 132 participants · Phase 2

    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  • NCT04128189 · 132 participants · Phase 3

    Shingrix in Renal Transplant Recipients

  • NCT04199780 · 132 participants · NA

    Effects of tDCS Combined With CBI on Postsurgical Pain

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01686620, the US trial registry maintained by the National Library of Medicine. NCT01686620 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.